SEC Form 4
NextCure, Inc. (NXTC) insider trading
In the 12 months to Nov 14, 2026, one NXTC insider reported open-market sales of $184.8K across 1 filing; one 10% owner bought $1.9M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $184.8K
- 1 filing · 1 insider
- Open-market purchases
- $1.9M
- 5 filings · Daniel Schneeberger, 10% owner
Who traded NXTC, and when
- Purchase
- Sale
NXTC daily close from Nov 14, 2025 to Nov 13, 2026, between $1.60 and $14.27, last $6.40. 1 sale and 5 purchase filings by 2 insiders, marked at their filing dates. Daniel Schneeberger, 10% owner: bought $1.9M across 5 filings, first filed Jul 29, 2026, last Nov 13, 2026. Renhong Tang, Other: sold $184.8K across 1 filing, first filed Aug 12, 2026, last Aug 12, 2026.
Largest mark · tap a row for others
Daniel Schneeberger · 10% owner
Filing 1 of 2 within a week · $1,711,833 total
Purchase $87,713
17,608 shares at $4.98 avg
Filed Jul 29, 2026 · traded Jul 27
Close on filing date $5.02
Daniel Schneeberger · 10% owner
10% owner
$1.9M boughtRenhong Tang · Other
Other
$184.8K soldOpen-market trades
6 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Daniel Schneeberger | 10% owner | — | $1.9M | 5 | — | |
| Renhong Tang | Other | $184.8K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Daniel Schneeberger 10% owner | Purchase | 12,333 | $5.10 | $62.9K | 750,289 | |
traded | Daniel Schneeberger 10% owner | Purchase | 4,686 | $5.10 | $23.9K | 737,956 | |
traded | Daniel Schneeberger 10% owner | Purchase | 10,851 | $4.95 | $53.7K | 733,270 | |
traded | Renhong Tang Other | Sale | 30,000 | $6.16 | $184.8K | 308,636 | |
traded | Daniel Schneeberger 10% owner | Purchase | 329,153 | $4.93 | $1.6M | 689,416 | |
traded | Daniel Schneeberger 10% owner | Purchase | 17,608 | $4.98 | $87.7K | 391,666 |
GET /stocks/filings/vX/form-4?tickers=NXTC&filing_date.gte=2025-11-14&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"NXTC"
],
"issuer_cik": "0001661059",
"owner_cik": "0001940272",
"accession_number": "0001940272-26-000032",
"form_type": "4",
"filing_date": "2026-11-13",
"period_of_report": "2026-11-11",
"issuer_name": "NextCure, Inc.",
"issuer_trading_symbol": "NXTC",
"owner_name": "ADAR1 Capital Management, LLC",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-11",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 12333,
"transaction_price_per_share": 5.0999,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 750289,
"transaction_value": 62897.066699999996,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnote",
"footnotes": [
{
"id": "F1",
"description": "The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.0750 to $5.1000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."
},
{
"id": "F2",
"description": "The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."
},
{
"id": "F3",
"description": "For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."
}
]
},
{
"tickers": [
"NXTC"
],
"issuer_cik": "0001661059",
"owner_cik": "0001861120",
"accession_number": "0001940272-26-000032",
"form_type": "4",
"filing_date": "2026-11-13",
"period_of_report": "2026-11-11",
"issuer_name": "NextCure, Inc.",
"issuer_trading_symbol": "NXTC",
"owner_name": "Schneeberger Daniel",
"is_director": false,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-11-11",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 12333,
"transaction_price_per_share": 5.0999,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 750289,
"transaction_value": 62897.066699999996,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "See Footnote",
"footnotes": [
{
"id": "F1",
"description": "The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.0750 to $5.1000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."
},
{
"id": "F2",
"description": "The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC."
},
{
"id": "F3",
"description": "For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has NextCure, Inc.'s CEO sold stock?
No. Michael Richman (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is NXTC’s insider data?
These are NXTC Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track NXTC insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for NXTC every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.